UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lapatinib in breast cancer

Annals of oncology, 2007-06, Vol.18 (suppl-6), p.vi26-vi30

2007

Volltextzugriff (PDF)

Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies

Annals of oncology, 2019-07, Vol.30, p.iv19-iv20

2019

Volltextzugriff (PDF)

The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v82-v82

2018

Volltextzugriff (PDF)

Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-06, Vol.29, p.v74-v74

2018

Volltextzugriff (PDF)

Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi22-vi23

2017

Volltextzugriff (PDF)

Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients

ESMO open, 2023-12, Vol.8 (6), p.102192-102192, Article 102192

2023

Volltextzugriff (PDF)

Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS

Annals of oncology, 2017-10, Vol.28, p.vi5-vi5

2017

Volltextzugriff (PDF)

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

ESMO open, 2023-02, Vol.8 (1), p.100748, Article 100748

2023

Volltextzugriff (PDF)

2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab

European journal of cancer (1990), 2015-09, Vol.51, p.S329-S329

2015

Volltextzugriff (PDF)

2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)

European journal of cancer (1990), 2015-09, Vol.51, p.S584-S584

2015

Volltextzugriff (PDF)

Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study

Annals of oncology, 2007-06, Vol.18 (suppl-6), p.vi128-vi132

2007

Volltextzugriff (PDF)

Stability of Behavioral and Emotional Problems Over 6 Years in Children Ages 4 to 5 or 6 to 7 at Time 1

Journal of emotional and behavioral disorders, 2010-09, Vol.18 (3), p.149-161

2010

Volltextzugriff (PDF)

422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)

Annals of oncology, 2022-09, Vol.33, p.S728

2022

Volltextzugriff (PDF)

Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL

Annals of oncology, 2006-01, Vol.17 (1), p.79-84

2006

Volltextzugriff (PDF)

P-68 Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study

Annals of oncology, 2022-06, Vol.33, p.S271

2022

Volltextzugriff (PDF)

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial

Annals of oncology, 2016-11, Vol.27 (11), p.2074-2081

2016

Volltextzugriff (PDF)

P-073Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Volltextzugriff (PDF)

399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial

Annals of oncology, 2020-09, Vol.31, p.S410-S411

2020

Volltextzugriff (PDF)

No significant association between four chromosome 18 gene variants and breast cancer in an Italian cohort of patients

Annals of oncology, 2016-09, Vol.27, p.iv75

2016

Volltextzugriff (PDF)

673PD - Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

Annals of oncology, 2019-10, Vol.30, p.v253-v254

2019

Volltextzugriff (PDF)

Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

Annals of oncology, 2019-10, Vol.30, p.v253-v254

2019

Volltextzugriff (PDF)

551P - Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

Annals of oncology, 2019-10, Vol.30, p.v208-v208

2019

Volltextzugriff (PDF)

Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

Annals of oncology, 2019-10, Vol.30, p.v208

2019

Volltextzugriff (PDF)

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

European journal of cancer (1990), 2021-05, Vol.148, p.190-201

2021

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lapatinib in breast cancer

Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies

The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress

Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients

Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab

2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)

Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study

Stability of Behavioral and Emotional Problems Over 6 Years in Children Ages 4 to 5 or 6 to 7 at Time 1

421P Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)

422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)

Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL

P-68 Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial

P-073Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies

399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial

No significant association between four chromosome 18 gene variants and breast cancer in an Italian cohort of patients

673PD - Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

551P - Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Suchergebnisse filtern